A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

NCT05660213 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

750

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Targeted drugs combined with anti-PD-1/PD-L1 antibodies
DRUG: TACE (transarterial chemoembolization) combined with targeted/immunotherapy
DRUG: Lenvatinib monotherapy
DRUG: Huaier granules combined with any of the above Cohorts for treatment

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]